ImmunityBio's Q1 2026 filing, a 10-Q submitted to the SEC on May 7, 2026 for the period ending March 31, 2026, confirmed what the revenue line suggested was a functional quarter while simultaneously exposing a financial structure that makes the company's $8.1 billion market capitalization difficult to reconcile with any conventional valuation framework. The company met its revenue estimate almost exactly, but the GAAP earnings miss, a net margin of -1,431.44%, and an operating margin of -157.88% describe a business that remains deeply unprofitable at the operating level. The print neither resolved the legal and regulatory pressures bearing down on the company nor provided a catalyst that would justify the stock's 274.90% 52-week appreciation.
The Result
Revenue came in at $44,206,000 against an estimate that implied a +0.02% surprise — effectively a flat match against consensus. The GAAP EPS, however, delivered a miss: actual EPS of -$0.08 against an estimate of -$0.07, a -0.14% negative surprise. The divergence between the near-perfect revenue match and the EPS miss reflects cost pressure that is not being absorbed by top-line performance.
A secondary and significant figure is the SEC-reported EPS of -$0.62, which diverges from the consensus-tracked figure of -$0.08. This gap is material and warrants scrutiny; it likely reflects adjustments or non-cash charges embedded in the GAAP computation that do not appear in the consensus-tracked adjusted figure. Investors relying on the headline beat risk misreading the underlying economics.
Print Scorecard
| Metric | Actual | Estimate | Surprise |
| EPS (consensus-tracked) | -$0.08 | -$0.07 | -0.14% |
|---|---|---|---|
| EPS (SEC GAAP, 10-Q filed 2026-05-07) | -$0.62 | — | — |
| Revenue | $44,206,000 | ~$44,197,000 implied | +0.02% |
| Gross Margin | 99.46% | — | — |
| Operating Margin | -157.88% | — | — |
| Net Margin | -1,431.44% | — | — |
Sources: SEC Form 10-Q, period ending 2026-03-31, filed 2026-05-07; consensus estimates from Benzinga as cited.
Narrative Test
The prevailing narrative entering this print was bifurcated: an active lawsuit alleging that ImmunityBio's Chairman materially overstated the capabilities of the company's drug pipeline, causing investor losses, sat alongside a retail momentum story that had driven the stock up 274.90% over the prior 52 weeks. That combination of legal overhang and speculative appreciation was already internally inconsistent, and the Q1 print did nothing to resolve the contradiction — it complicated it further.
The revenue match and absence of any guidance revision could be read, in isolation, as stabilizing. Management provided no changes to guidance, which in a conventional context would be neutral to mildly positive. But in the context of a stock trading at a market capitalization of $8.1 billion against a business generating $44.2 million in quarterly revenue — annualizing to roughly $176.8 million — and burning cash at an operating margin of -157.88%, the narrative of fundamental justification for current prices is not confirmed by this print. It is contradicted by it.
The lawsuit narrative, meanwhile, draws its credibility not from malice but from the valuation gap itself. When a stock trades at more than three times what discounted cash flow or peer-multiple analysis implies is fair value, the gap between what is being communicated and what the financials support becomes structurally significant. This print did not narrow that gap.
Forensic Dissection
The 99.46% gross margin is the single legitimately strong line item in this filing. For a biopharmaceutical company at ImmunityBio's stage, near-100% gross margin signals that the product economics — specifically for Anktiva, the BCG-unresponsive non-muscle invasive bladder cancer treatment — are highly favorable on a per-unit basis. There is no meaningful cost of goods sold degrading the revenue dollar.
That strength, however, collapses immediately below the gross line. An operating margin of -157.88% means the company is spending roughly $2.58 in operating expenses for every dollar of revenue generated. Research and development, selling, general and administrative, and other operating costs are running far in excess of what the current revenue base can support. This is not unusual for a company at this commercial stage, but it does mean that the path to operating breakeven requires either a dramatic step-change in revenue — Anktiva volumes expanding by multiples — or a structural reduction in the operating cost base, neither of which this quarter's print signaled.
The net margin of -1,431.44% is the most alarming single figure in the filing. A net margin of this magnitude implies material non-operating charges — interest expense, debt service, or other below-the-line items — are compounding the operating loss significantly. This is consistent with the spread between the consensus-tracked EPS of -$0.08 and the GAAP EPS of -$0.62 filed with the SEC. Investors should identify the specific line items driving the below-operating-income deterioration; that figure is not visible in the aggregate data provided here but is disclosed in the 10-Q filed May 7, 2026.
No guidance changes were issued. In context, the absence of an upward revision carries more weight than the absence of a downward one — the revenue base remains too narrow to materially shift the loss profile within the next two to three quarters without a significant commercial acceleration.
Four-Bullet Watchlist
- Anktiva commercial uptake data: Quarterly revenue from the bladder cancer indication must show sequential growth sufficient to bend the operating margin trajectory; flat or decelerating volume would further undermine the bull case.
- Legal proceedings disclosure: The 10-Q filed May 7, 2026 will contain updated litigation language; any expansion of the lawsuit's scope, additional named defendants, or settlement discussions will carry direct narrative consequences.
- Below-the-line charge composition: The spread between GAAP EPS of -$0.62 and consensus-tracked EPS of -$0.08 requires itemization; debt restructuring, warrant revaluations, or accelerating interest expense would signal worsening financial flexibility.
- Short interest trajectory: At 36.13% of float short, any sustained volume event, FDA decision, or litigation development could trigger a mechanically dislocated move in either direction — monitor weekly for changes in short positioning.
ImmunityBio's Q1 print demonstrates that a near-100% gross margin profile, by itself, cannot bridge a -157.88% operating margin, a $8.1 billion valuation, and a legal narrative whose core allegation — that disclosed capabilities do not match investor expectations — finds a structural analog in the gap between the company's current market price and what its underlying financials, as reported in the May 7, 2026 10-Q, can support.